Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: capecitabine

« Back to Dashboard

Summary for Generic Name: capecitabine

Drug Master File Entries: see list26
Suppliers: see list3

Pharmacology for Ingredient: capecitabine

Clinical Trials for: capecitabine

LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
Status: Completed Condition: Breast Cancer

A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Status: Completed Condition: Advanced Solid Tumors

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
Status: Recruiting Condition: Breast Cancer

Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
Status: Completed Condition: Metastatic Breast Cancer

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
Status: Terminated Condition: Hepatocellular Carcinoma

Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
Status: Recruiting Condition: Breast Neoplasms; Neoplasms by Site; Neoplasm Metastasis; Breast Diseases; Skin Diseases

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Status: Completed Condition: Pancreatic Cancer

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer
Status: Completed Condition: Metastatic Colorectal Cancer; Responsive to Fluoropyrimidines; Advanced Colorectal Cancer; Neoplasms, Colorectal

Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
Status: Active, not recruiting Condition: Pancreatic Cancer

Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study
Status: Completed Condition: Elderly Patients; Breast Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hoffmann La Roche
TABLET;ORAL020896Apr 30, 1998RXYes5,472,949*PED<disabled>Y<disabled>
Teva Pharms Usa
TABLET;ORAL091649Sep 16, 2013RXNo<disabled><disabled>
Mylan Pharms Inc
TABLET;ORAL090943Aug 8, 2014RXNo<disabled><disabled>
Hoffmann La Roche
TABLET;ORAL020896Apr 30, 1998RXYes<disabled><disabled>
Hoffmann La Roche
TABLET;ORAL020896Apr 30, 1998RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn